MetaCap

Tango Therapeutics (TNGX) vs Viridian Therapeutics (VRDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tango Therapeutics (TNGX) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 116.7% versus a loss of 1.3%. Over five years, TNGX leads with a +110.0% price change compared with +63.7% for VRDN. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.40 billion), about 1.1 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs +48.3%).

Tango Therapeutics converts more of its revenue into profit, with a net margin of -162.9% versus -483.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TNGX+116.65%VRDN-1.25%
+242%+86%-70%
Nov 21, 20251 yearNov 20, 2026
TNGX+81.54%VRDN+54.04%
+176%+36%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TNGX versus VRDN key metrics
MetricTNGXVRDN
Share price$21.73$29.96
Market cap$3.68B$3.40B
1-day change-4.32%-4.71%
YTD return+145.26%-3.73%
1-year return+116.65%-1.25%
5-year return+109.95%+63.72%
EPS (TTM)$-1.38$-3.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$62.38M$70.85M
Revenue growth (YoY)+48.29%+23359.93%
Net income (latest FY)$-101.59M$-342.60M
Operating margin-178.39%-512.91%
Net margin-162.85%-483.57%
52-week high$34.39$34.29
52-week low$8.30$13.18
Distance from 52-week high-36.81%-12.63%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+116.29%+42.72%
Average volume3.41M2.14M
Shares outstanding169.46M113.56M
Employees137252
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TNGX has outperformed VRDN by 117.9 percentage points over the past year.
  • Tango Therapeutics is more profitable, keeping -162.9 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
  • Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +48.29%).

About Tango Therapeutics

TNGX stock →

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

TNGX vs VRDN FAQ

Which is bigger, Tango Therapeutics or Viridian Therapeutics?

Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.40B for Viridian Therapeutics (VRDN).

Which stock has performed better over the past year, TNGX or VRDN?

TNGX returned +116.65% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.

Are Tango Therapeutics and Viridian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons